Wilms Tumor 1 (WT1) (N-Term) Peptid
WT1
Reaktivität: Human
Wirt: Synthetic
WB, BP
-
- Target Alle WT1 Produkte
- WT1 (Wilms Tumor 1 (WT1))
- Protein Region
- N-Term
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Western Blotting (WB), Blocking Peptide (BP)
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-WT1 antibody (Catalog #: ARP37988_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Aufreinigung
- Purified
-
-
- Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Konzentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- WT1 (Wilms Tumor 1 (WT1))
- Hintergrund
-
WT1 is a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms.This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
Alias Symbols: AWT1, GUD, WAGR, WIT-2, WT33, NPHS4, EWS-WT1
Protein Interaction Partner: AREG,CIAO1,CREBBP,FHL2,PAWR,PAX2,PRKACA,TP53,TP63,TP73,U2AF2,UBE2I,WTAP,WTIP,PAWR,Pawr,TP53,U2AF2,UBE2I,WTAP
Protein Size: 514 - Molekulargewicht
- 56 kDa
- Gen-ID
- 7490
- NCBI Accession
- NM_000378, NP_000369
- UniProt
- E9PMK7
-
Sie sind hier:
